华大：源起人类基因组计划，取得众多顶尖科研成果
Start From the Human Genome Project to Receive Many Leading Scientific Achievements
1999年，为承担人类基因组计划“中国部分”（1%计划），华大注册成立。中国成为唯一加入该计划的发展中国家。截至2018年6月，华大累计发表论文超2500+篇，国际顶级学术期刊收录300+篇。华大在知识产权方面已申请国内外专利2683件，已获得授权发明专利 841件。
In 1999, BGI was established for taking part in Human Genome Project (HGP). At that time China was the only developing country which participated in the HGP. Since then, BGI has accumulatively published over 2500 academic articles, including more than 300 articles published on top international journals. Till June 2018, BGI has 2683 intellectual properties applied for patents, and 678 have been granted.
急人民之所急，办抗病之所需
Actively take responsibilities for the people and the country’s benefit
华大多次参与国家突发公共卫生事件的应急处理。非洲埃博拉疫情，华大派先遣队赶赴塞拉利昂；德国大肠杆菌疫情，华大率先破译大肠杆菌全基因组，成功研制诊断试剂盒并无偿公开检测方法；中国抗击“非典”中，协同完成了中国首例SARS病毒的基因组序列，并无偿捐赠30万人份SARS病毒诊断试剂盒。
BGI has made great contributions to deal with some emergent crucial public health crises. During the African Ebola Crisis, BGI sent a vanguard to Sierra Leone; In Escherichia coli outbreak in Germany, BGI firstly deciphered the whole genome of Escherichia coli, invented the diagnostic kit and published the open-access research results. In China, BGI was the first one completing the genome sequencing of SARS, invented SARS virus diagnostic kits and donated 300,000 to the country without any charges.
深圳国家基因库：中国首个国家级基因库
China National Genebank: The first national gene bank in China
2011年，国家发展改革委员会批复同意依托深圳华大生命科学研究院（原名为深圳华大基因研究院）组建深圳国家基因库。
In 2011, the National Development and Reforming Committee authorized the establishment of the China National Genebank based on BGI Research.
打通产业链，引领产业发展
2013年，华大全资收购美国上市公司Complete Genomics（CG），并迅速实现技术的转化与再创新。目前全球只有中美两国、三家公司可以量产临床级别测序仪，华大是其中之一。
2017年7月14日，深圳华大基因股份有限公司正式挂牌上市。
In 2013, BGI acquired the American publicly traded company-Complete Genomics (CG) followed by accelerating the transfer and creation of technologies. Up to now there are only three companies in two countries which can mass produce clinical sequencers. BGI is one of them.
On July 14, 2017, BGI’s subsidiary – BGI Genomics was listed in the Shenzhen Stock Exchange.
华大从员工自我实践做起，形成了跨组学生命数字化的，从健康指标建立到精准干预和健康提升的闭环方案。践行造福人类，美好人生，从我做起！
Starting from self-practice among the employees, BGI has developed a digitalized trans-omics closed loop plan from health indexes establishment, precision intervention and health improvement. BGI is walking on the way to benefit and bring wonderful life to all human beings starting from self-practice!
